Xenon Pharmaceuticals Inc (XENE)

Sep 21, 2026

Xenon Pharmaceuticals (XENE) stock dropped 31% after the company paused enrollment in its Phase 3 studies for major depressive disorder and bipolar disorder due to higher rates of neuropsychiatric side effects. While the X-NOVA2 trial for major depressive disorder is still expected to report results in Q1 2027, analysts have reacted by cutting price targets and downgrading the stock, raising concerns about the drug's psychiatric potential. The company plans to adjust dosing before potentially resuming these trials.

Sep 18, 2026

Xenon Pharmaceuticals' stock plummeted 30% after the company announced it was submitting a New Drug Application for azetukalner for focal seizures, but also pausing trials for major depressive disorder and bipolar depression. This setback for Xenon could benefit a rival biotech company that has faced similar pressures. The article highlights that what should have been a milestone for Xenon was overshadowed by this clinical setback.

Sep 17, 2026

Xenon Pharmaceuticals has temporarily halted new patient enrollment in clinical trials for its experimental depression drug due to reports of mental and nervous system-related side effects, including confusion, speech difficulties, and rare cases of psychosis. Shares of Xenon tumbled over 25% following the announcement. The company is evaluating potential dose adjustments and emphasized that its epilepsy program for the same drug remains unaffected, with an FDA application already submitted for focal seizures.